CRE Homepage About The CRE Advisory Board Newsletter Search Links Representation Comments/Ideas
Reg Week Archives
Data Access
Data Quality
Regulation by Litigation
Regulation by Information
Regulation by Appropriation
Special Projects
CRE Watch List
Emerging Regulatory Issues
OMB Papers
Guest Column
Voluntary Standards Program
CRE Report Card
Public Docket Preparation
Interactive Public Docket
Electronic Regulatory Reform
Consumer Response Service
Site Search

Enter keyword(s) to search
CRE Watch List: Special Projects

Human Volunteer Research

CRE Data Quality Act Petitions

Background Materials
United States Government Resources
Private and Non-Government Resources
CRE Data Quality Act Petitions

Information Quality Guidelines: EPA Ban on Third Party Clinical Human Test Data Violates Data Quality Act
CRE has informed EPA that the agency's ban on third party clinical human test data, pending National Academy of Sciences (NAS) review, violates the Data Quality Act. In its letter to EPA, the Center points out that these data are among the best available information regarding any substance's risk to human health, and the Act requires the agency to consider and use the best available data on health risks. Therefore, EPA's categorical refusal to consider these data is a clear violation of the Act and OMB's implementing Data Quality guidelines. CRE urges EPA to change its position now. CRE is including this letter as part of its comments on EPA's proposed Data Quality guidelines.

  • Click to read CRE's letter to EPA
  • Click to read Exhibits to the CRE letter
  • CRE Regulatory Services
  • Click to submit a comment

  • Leave a Comment